Mucopolysaccharidosis (MPS) refers to a group of rare, inherited metabolic disorders caused by the body's inability to produce enough of certain lysosomal enzymes needed to break down complex sugar molecules called glycosaminoglycans (GAGs). This enzyme deficiency leads to a harmful buildup of substances like dermatan sulfate, heparan sulfate, and keratan sulfate in the body's cells, resulting in progressive organ damage and, in many cases, severe neurological complications. Given the chronic and life-limiting nature of these disorders, the Mucopolysaccharidosis Treatment Market has become an area of intense pharmaceutical research and investment, particularly as companies race to develop therapies capable of addressing both the systemic and neurological manifestations of the disease.
Market Size and Growth Trajectory
The global mucopolysaccharidosis treatment market stood at USD 3.96 billion in 2025 and is expected to grow to USD 4.37 billion in 2026, eventually reaching USD 9.74 billion by 2034, registering a compound annual growth rate (CAGR) of 10.54% during the forecast period, according to Fortune Business Insight. This robust growth outlook reflects both the rising diagnosis rates of rare metabolic disorders and the expanding pipeline of advanced therapeutics designed to overcome the limitations of existing treatments.
Understanding the Disease and Treatment Landscape
MPS encompasses several distinct subtypes, including MPS I (Hurler syndrome/Hurler-Scheie syndrome/Scheie syndrome), MPS II (Hunter syndrome), MPS IV A (Morquio A syndrome), MPS VI (Maroteaux–Lamy syndrome), and others such as MPS VII (Sly syndrome). Each subtype arises from a deficiency in a different enzyme, but all share the common thread of GAG accumulation leading to multi-organ dysfunction. Enzyme Replacement Therapy (ERT) is expected to dominate the treatment landscape, projected to hold a 93.89% share of the market in 2026, according to Fortune Business Insight. ERT works by supplying the missing enzyme intravenously, and products such as Elaprase (idursulfase) for Hunter syndrome, Vimizim (elosulfase alfa) for Morquio A syndrome, and ALDURAZYME for MPS I have become the backbone of treatment protocols worldwide.
Among disease types, MPS II (Hunter syndrome) is projected to dominate with a 24.25% market share in 2026, driven largely by the strong commercial presence of products like Elaprase and Hunterase, according to Fortune Business Insight. By route of administration, intravenous delivery is expected to account for 98.16% of the market in 2026, since nearly all approved MPS therapeutics require this mode of administration, with Hunterase being a notable exception delivered via the intracerebroventricular (ICV) route, according to Fortune Business Insight.
Key Market Drivers
A central driver of this market is the significant unmet clinical need stemming from the limitations of current ERT options. Many existing therapeutics, including Elaprase and ALDURAZYME, cannot cross the blood-brain barrier, which means they fail to address the debilitating neurological symptoms that affect a large proportion of MPS patients, particularly those with severe Hunter syndrome. This gap has spurred a wave of research into next-generation treatments, including gene therapy and hematopoietic stem cell transplantation (HSCT), with companies like Sangamo Therapeutics actively pursuing gene therapy candidates for Hunter syndrome.
The rare disease nature of MPS has also attracted substantial investment from biopharmaceutical companies, since orphan drug development often carries a higher probability of achieving blockbuster status compared to therapies for more common conditions. Prominent clinical-stage companies such as ArmaGen, Denali Therapeutics, and REGENXBIO Inc. are advancing pipeline candidates across various MPS subtypes, reflecting sustained industry confidence in the commercial and therapeutic potential of this space.
Market Restraints
Despite this promising growth outlook, the market faces notable restraints. ERT remains prohibitively expensive, with some therapies costing hundreds of thousands of dollars annually, placing them out of reach for patients in developing and emerging economies. This cost barrier, combined with inadequate reimbursement infrastructure and limited disease awareness in many regions, continues to suppress treatment rates even as diagnostic capabilities improve globally. Diagnostic delays also remain a persistent challenge; research published in the Orphanet Journal of Rare Diseases has highlighted ongoing difficulties in shortening the time to diagnosis for ultra-orphan MPS subtypes such as MPS I and MPS III, further restraining timely treatment initiation.
Regional Insights
North America led the global market, accounting for a 52.10% share in 2025, supported by strong reimbursement frameworks, high diagnostic sophistication, and a dense concentration of clinical-stage biopharmaceutical companies, according to Fortune Business Insight. Europe held the second-largest share at 22.41% in 2025, with growth supported by established products like Elaprase and ALDURAZYME. Asia Pacific, while currently smaller at 20.13% of the global share in 2025, is projected to register the highest regional CAGR during the forecast period, driven by anticipated product launches and a substantial untapped patient population, according to Fortune Business Insight.
Competitive Landscape
The competitive landscape remains concentrated among a handful of established players. Shire, now part of Takeda Pharmaceutical Company Limited, maintains a dominant position through Elaprase, while BioMarin holds a diversified portfolio including ALDURAZYME, VIMIZIM, and NAGLAZYME. Other notable companies profiled in the market include Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, Lysogene, Abeona Therapeutics Inc., Ultragenyx Pharmaceutical, and Genzyme Corporation. Recent industry developments underscore the sector's momentum: Lysogene received FDA fast track designation for its LYS-SAF302 gene therapy targeting Sanfilippo syndrome in February 2020, Abeona Therapeutics secured a similar designation for ABO-101 in April 2019, and Ultragenyx achieved European approval for Mepsevii in August 2018 for the treatment of Sly syndrome.
Outlook
As the mucopolysaccharidosis treatment market continues to evolve, the interplay between rising unmet clinical needs, an expanding pipeline of gene and cell-based therapies, and persistent affordability challenges in emerging markets will shape its trajectory through 2034. Continued regulatory support for rare disease therapeutics, alongside anticipated new product launches, positions this market for sustained double-digit growth in the years ahead.
What's Driving Japan's Market? Discover the Latest "Mucopolysaccharidosis Treatment Market" Insights
https://www.fortunebusinessinsights.com/jp/%E3%83%A0%E3%82%B3%E5%A4%9A%E7%B3%96%E7%97%87%E6%B2%BB%E7%99%82%E5%B8%82%E5%A0%B4-102551